Supercharged immune cells take on Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a new type of cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recognize and attack c…
Phase: PHASE1 • Sponsor: TingBo Liang • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC